<DOC>
	<DOC>NCT00363857</DOC>
	<brief_summary>A 14-Week clinical research study to compare the effectiveness and safety of ropinirole and placebo (an inactive sugar pill) in the treatment of patients with Restless Legs Syndrome (RLS) in the United States.</brief_summary>
	<brief_title>A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Inclusion criteria: Patients diagnosed with Restless Legs Syndrome (RLS) with symptoms such as: uncomfortable or "creepycrawly" sensations in your legs, overwhelming urge to move your legs to relieve these sensations, sensations go away when you move your legs, or trouble falling asleep or staying asleep because of these symptoms. Patients must give written informed consent prior to any specific study procedures. Exclusion criteria: Patients who suffer from narcolepsy, sleep terror disorder, sleepwalking disorder, or a breathing related sleep disorder. Patients diagnosed with renal failure (endstage renal disease) iron deficient anemia or pregnancy. Patients suffering from other movement disorders (i.e. Parkinson's Disease). Patients who have medical conditions such as diabetes, peripheral neuropathy, rheumatoid arthritis, or fibromyalgia syndrome. Participation in any clinical drug or device trial in the last three months. Other inclusion or exclusion criteria to be evaluated by the physician.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>fatigue</keyword>
	<keyword>sleep</keyword>
	<keyword>sleep disorder</keyword>
	<keyword>Legs</keyword>
	<keyword>RLS</keyword>
	<keyword>Restless Legs Syndrome</keyword>
	<keyword>Ropinirole</keyword>
</DOC>